Numab Therapeutics AG Revenue and Competitors
Estimated Revenue & Valuation
- Numab Therapeutics AG's estimated annual revenue is currently $13M per year.
- Numab Therapeutics AG's estimated revenue per employee is $155,000
- Numab Therapeutics AG's total funding is $223M.
Employee Data
- Numab Therapeutics AG has 84 Employees.
- Numab Therapeutics AG grew their employee count by -10% last year.
Numab Therapeutics AG's People
Name | Title | Email/Phone |
---|
Numab Therapeutics AG Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Numab Therapeutics AG?
Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCHâ„¢ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes.
keywords:N/A$223M
Total Funding
84
Number of Employees
$13M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Numab Therapeutics AG News
Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter...